Atreca Reports Fourth Quarter and Full-Year 2022 Financial R

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression... | March 29, 2023

Related Keywords

Philippe Bishop , Herb Cross , John Orwin , Xencor Xmab , Alex Gray , Gates Medical Research Institute , Atreca Inc , Exchange Commission , Xencor Inc , Melinda Gates Medical Research Institute , Chief Executive Officer , H Score Preclinical Pipeline , Recent Developments , Chief Medical , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Consolidated Statements , Atreca , Nc Stock Exchange , News , Information , Press Release , Ontinues , O , The , Fell , Ctolerated , N , Ngoing , Hase , Tb , Linical , Activity , Bserved , Multiple , Humor , Longer , Progression , Tree , Survival , Patients , Ith , Thigh , Arget Bcel Us04965g1094 ,